Author(s)

Mingrui Hu, Jocelyn Jinyueran Ni

Corresponding Author

Jocelyn Jinyueran Ni

ABSTRACT

Tuberculosis has been a prevailing disease across the globe, threatening millions of people’s lives. With the mutation in mycobacterial cells, the number of drug-resistant tuberculosis bacteria and widely drug-resistant tuberculosis bacteria is increasing rapidly. The first line drugs such as Ethambutol, Rifampicin, and Pyrazinamide fail to control the spread of those tuberculosis, stressing the demand for new treatment to combat the infectious disease. Delamanid, a recently approved drug by the FDA, gives hope in tackling the surging number of Tuberculosis disease. Delamanid is effective in destabilizing the mycobacterial cell wall, thus can enter and destroy the bacteria. Clinical trials in China, South Korea, and Latvia all show positive results - Delamanid is effective and safe. Its positive clinical trials show the drug’s promising effect. However, possible side effects such as causing heart rhythm problems and the lack of human clinical trials should be taken into consideration, especially when implementing delamanid in Tuberculosis treatments. By assembling and analyzing the current research on Delamid and its effects on the disease, we review the current problems of tuberculosis human beings face, delamanid as the possible solution, its mechanism and effectiveness of addressing the disease. In total, Delamanid is proven to be a promising regimen of tuberculosis and can be broadly applied with more reassuring clinical trials.

KEYWORDS

Delamanid, tuberculosis, Multidrug-resistant tuberculosis, extensively drug resistant tuberculosis